Front Pharmacol 2022;13:1026182
**BPC-157, a synthetic gastric pentadecapeptide studied primarily in animal models for tissue repair, gut healing, and anti-inflammatory effects, remains unapproved by the FDA as a finished drug with only limited small-scale human data available.** It was placed in Category 2 in 2023 due to concerns over immunogenicity, peptide impurities, and insufficient safety information for compounding under Section 503A
Additionally, it has beneficial effects on patients glycemic and blood pressure control, serum high-sensitivity C-reactive protein (hs-CRP) levels, total cholesterol/HDL cholesterol ratio, total cholesterol, and mental health parameters [209]
doi: 10.1074/jbc.M602048200
Abdominal pain Headache Low blood sugar Constipation Fatigue Nausea Vomiting Diarrhea Dizziness Acid Reflux For the majority of individuals, symptoms tend to be mild and resolve spontaneously over time
They bind to GLP-1 receptors throughout the body and produce a prolonged version of the natural response, dramatically reducing hunger, improving insulin sensitivity, and driving significant weight loss
